The Journal of Human Hypertension has now cominated in a conference centre converted from a beautiful old farmhouse in Finland near the town of pleted its first 10 years so perhaps the time has come to look back at our successes, our unfulfilled Tuohilampi. Jeremiah and Rose Stamler and Michael Marmot gave the participants of the First ambitions and think of the future. The Journal was initially founded on the basis of an expression of Advanced Seminar on Cardiovascular Epidemiology the task of devising a project to answer Sir George irritation on the part of many clinicians on the domination of the hypertension literature by papers on Pickering's objections to the salt hypothesis of hypertension. 2 During the 2 weeks of this residential molecules and laboratory animals. Whilst no one would denigrate the contribution of basic scientists course, the participants devised a project which later became known as INTERSALT. to the field of hypertension, the role of clinicians and epidemiologists seemed to us to have been Whilst the main findings of the INTERSALT Project were published in the British Medical Journal under-recognised. The success of the Journal over the last 10 years and the unsolicited testimonials we in 1988, the Journal of Human Hypertension was pleased to publish the crude unadjusted data in a have received suggest that may be we have got the mix about right. We said in our original declaration special issue so that scientists anywhere in the that we wished to act as encouragers of medical world could investigate the INTERSALT data at research as well as disseminators of information. 1 source. 3 Parts of that particular issue of the Journal We are pleased, therefore, to have been able to do not make particularly riveting reading as it conaccept many papers from the developing countries.
tains 76 pages of detailed tables. It is probable, howWhilst these studies have not told us anything new ever, that we made the correct decision in deciding at a scientific level, they have made an important to accept the INTERSALT data file in one special contribution to the worldwide awareness of hyperissue. The INTERSALT Project came under criticism tension. We have not opted to lower our standards from the food industry whose manoeuvres do no but we have been sympathetic to largely descriptive credit to the interface between commercial considerstudies from countries which do not have a tradition ations and scientific research. The INTERSALT Coof biomedical research.
operative Research Group could not, however, be As we enter our second decade, it is perhaps accused of withholding their data because they were worthwhile for us to review some of the recent there for all to see. The 1996 re-analysis of the events in hypertension and to gauge whether we INTERSALT data and the attempts on the part of the have been correct in our acceptance of papers on salt industry to analyse the data in their own way various topics.
are of great interest. The most important epidemiological event of the Pressure. This study will look at nutritional factors last 10 years was the publication of the INTERSALT and BP in enormous detail. INTERMAP, which is Project. This was the biggest ever international epideffectively an extension of the INTERSALT project emiological study of the relationship between salt will undoubtedly be one of the most important epidintake and blood pressure (BP) which was convened emiological events at the time of the millennium. by Geoffrey Rose, Michael Marmot and Jeremiah
The other epidemiological papers published by Stamler as well as Paul Elliott. Fifty-two populations the Journal have largely been on a 'one-nation' basis. were studied simultaneously in 32 countries using On the whole they tend to confirm the marked strictly standardised techniques and data of superb quality were obtained. The INTERSALT Project origurban/rural differences in BP and these differences remain hard to explain. Whilst body mass index, salt considerations like cuff size and speed of deflation of mercury column as well as patient related factors intake and in some populations alcohol intake are major environmental causes of high BP, clearly there and the patient/doctor interaction. We await with trepidation the possible abolition of mercury manare other environmental and nutritional factors which need to be examined. The importance of ometers from countries in the European Union, and we greet with horror the arrival of kilo-pascals as many of the urban/rural comparisons that have been published is that the differences cannot be the unit of measuring BP although this would be the logical development if mercury manometers were to explained by genetic factors alone, although there may be genetically rated predispositions to these be abolished. 12 We hope that the non-European nations will oppose the widespread adoption of environmental factors, in particular salt intake. these 'progressive' changes which will be hard to implement anyway particularly in developing coun-
Ethnicity
tries. We were delighted to devote one whole issue of the Journal to a Meeting of the International Society for
Awareness of BP
the Study of Hypertension in Blacks. 6 The issue of hypertension in people of African origin remains a A great many studies were published in the late 1990s which confirmed the depressing state of source of great interest and concern. It is important not to look at all people of an African origin as a underdiagnosis and undertreatment of hypertension, even in advanced prosperous countries. The single group but to differentiate between them. In rural Africa, in underdeveloped, low salt-consuming increasing awareness of the importance of hypertension amongst primary health care workers does not societies, hypertension is rare. By sharp contrast, in the USA the prevalence of hypertension in the black as yet seem to have any major payoff in terms of improved detection and management. A recent population is about twice that seen amongst whites. In the UK there appears to be an intermediate pic-
study from the USA still shows a depressing level of suboptimal care in the management of hypertension, ture where the average BP of black people in London and Birmingham does not appear to be substantially although one has to say that the criteria for optimal care are now stricter than they used to be. 13 different from white subjects. However, the fact remains that the detection and management of hypertension in black people is of a very low stanPharmacotherapy dard although the reasons for this are not entirely certain. In the UK, where there are substantial AfroThe most important pharmacological event over the last decade has been the introduction of the angioCaribbean and Indo-Asian minority groups, sharp differences have emerged. In the Indo-Asian poputensin receptor antagonist, losartan. This could be regarded as a 'designer drug' in the sense that Peter lation, which contains a significant number of people who cannot speak English, the outlook for Timmermans specifically set out to synthesise a non-peptide angiotensin receptor antagonist. 14 We malignant phase hypertension is not bad whereas the Caribbean origin patients with the same diagare pleased that many of the fundamental clinical papers on losartan were published in the Journal of nosis have a very poor prognosis. 7 The difference between the ethnic groups, however, did not appear Human Hypertension. 15 It is quite apparent that the angiotension receptor antagonists do represent a to be related to ethnicity itself. Black patients with their poor prognosis often present for clinical care major breakthrough, and this is witnessed by the decision of a great many pharmaceutical companies with higher BPs and more renal failure at the outset. Careful statistical analysis shows that, taking into to develop their own compounds in the same group. We look forward with interest to see whether there account all confounding variables, there appears to be no true ethnic difference in the clinical course are any differences between the various angiotensin receptor antagonists and whether these agents will of this particular form of hypertension. 8 The black subjects have higher BPs and present later with have the same or even better beneficial effects as the angiotensin-converting enzyme (ACE) inhibitors. more end-organ damage. The implications of this finding need to be translated into further research.
Furthermore, the use of these agents will undoubtedly teach us a great deal about the role of the reninangiotensin system in hypertension, renal impair-
BP measurement
ment and congestive cardiac failure. The first meta-analyses comparing the use of ACE The topic of BP measurement is of great interest to all three of the Editors of this Journal. We have, inhibitors against other drugs in the regression of left ventricular hypertrophy was published in the therefore, been very pleased to publish a whole series of articles on the development of non-invasive Journal of Human Hypertension by John Cruickshank and his findings were subsequently confirmed BP machines including 24-h ambulatory BP systems.
9 It seems to us that the problems of sphygmoby other authors. 16 The advent of the long acting alpha receptor manometry have not been solved even during 1996 when we celebrated the centenary of the invention blockers, doxazosin and terazosin has perhaps had a less impressive impact on medical care. 17, 18 Howof the first manometer by Scipione Riva-Rocci in Turin in 1896.
10,11 A great many factors influence ever, these drugs are very attractive as they appear to have beneficial effects on serum cholesterol levels the BP of an individual patient at one particular moment in time, and these are related to technical and there are no contraindications. Furthermore, it is likely that they do have modestly beneficial
The history of hypertension effects on sexual function in men. They are also It is probable that the best research may be conduchelpful in hypertensive men who are symptomatic ted by those who are aware of the past whilst thinkfrom prostatic hyperplasia but they can cause stress ing of the future. The Journal of Human Hypertenincontinence in women. The alpha-blockers can sion has, for that reason, been happy to commission be regarded as a useful addition to our therapeutic a series of articles on the history of hypertension and armamentarium but no new ground has been BP measurement, as well as biographical articles broken.
about some of the important contributors to the On the horizon we have the development of the field. Stephen Hales, Frederick Henry Horatio Akbar imidazoline receptor agonists. The first, rilmenidMahomed and Theodore Janeway have been covered ine, is available in some countries and moxonidine so far, and a further article on Mahomed and one on has also recently been launched. A review article of Richard Bright will soon be published. 24-26 Professor moxonidine and related compounds will be pub-ET O'Brien's review of the 'History of blood pressure lished shortly in the Journal of Human Hypertenmeasurement' have been a worthwhile addition to sion. In theory, these drugs, which have a high our pages, as has been the publication of the panels affinity for the central imidazoline receptors but on this topic which were on display at the Glasgow have few central alpha agonist effects, may reduce Meeting of the International Society of Hypertension BP without the side effects which were encountered in 1996.
10, 11, 27 with methyldopa and clonidine. The activity of a synthetic nervous system has emerged as a powerful risk factor for a variety of car-
The future diovascular disorders such as atherosclerosis, left
The main problems for the future will be similar to ventricular hypertrophy, glucose intolerance, the ones of the past. That is, how do we deliver valiarrhythmias and congestive heart failure. Antihyperdated health care to millions of people? We know tensive therapy that elicits sympathetic stimulation that antihypertensive treatment is effective in premay be less beneficial for a given decrease in arterial venting both heart attacks and strokes and we know pressure than therapy that reduces the activity of the that many of the cardiovascular calamities that do sympathetic nervous system. Conceivably the bad occur could have been prevented were antihypertenpress of the calcium channel blockers may be related sive treatment administered on a systematic and to the inappropriate use of short acting agents in efficient basis. This problem will not go away so we high dose with the resulting sympathetic stimuwill continue to show particular interest in the problation. There is good evidence that such sympathetic lems of health care delivery in both developed and stimulation is less pronounced or lacking with the developing countries. The most important pharmanewer, better tolerated, long acting calcium chancological events in the future will unfortunately not nel blockers.
occur until after the year 2000, when a great many During 1995 there was a considerable stir amongst studies will be published comparing the different hypertensionologists following the publication by therapeutic subclasses of antihypertensive drugs to Psaty and colleagues of a series of papers suggesting investigate whether any one class is any better than that calcium channel blockers may cause cardiac any other in the prevention of heart attacks, strokes death, a variety of cancers and gastro-intestinal or renal impairment. There is quite good evidence haemorrhage. 19 The Journal of Human Hypertension that the ACE inhibitors are better than the other published a useful review of these papers and came drugs at effecting the surrogate end-points of left to the general conclusion that the findings of these ventricular hypertrophy and proteinuria, but as yet workers must be treated with considerable caution there is no reliable information about the prevention as they are not based on the gold standard of ranof the hard end-points, heart attack and stroke. domised controlled trials. 20 The debate still rages The ALLHAT study in the USA and the ASCOT and in the meantime there is general agreement that study in the UK and Scandinavia are exciting new short-acting nifedipine should not be used in high ventures but we will have to be patient as there will dose. We were not, however, under the impression be no results until well into the next millenium that many clinicians had been doing this anyway.
( Table 1 ). The Hypertension Optimal Treatment Whilst this Journal is primarily concerned with (HOT) Study is likely to be published sooner and clinical issues, we have attempted to accept a will substantially influence clinical practice as it reasonable number of papers on clinical aspects of will tell us by how much we should reduce BP and basic science. Thus we are pleased to have been able whether aspirin is useful. Similarly the Syst-Eur to contribute to the world literature on the topic of Study will also be published fairly soon and this the powerful vasoconstrictor, endothelin, and we will tell us more about the value of treating isolated have also taken an interest in the field of the isosystolic hypertension in the elderly. 28 lation of the ACE gene and its impact on renal syndromes. It seems to us that a high priority for further research should be the identification of the gene
The Journal and its supporters
which controls the sensitivity to dietary salt intake. We have also published special issues devoted to Over the last 10 years we have had several sadnesses. The premature death of Daniel Savage and the topics of hypertension and the kidney, 21 diabetes 22 and BP in children, 23 as well as several issues Tony Raine, both of whom were enthusiastic supporters of this Journal, has deprived the medical on hypertension in the community. In addition, many pharmaceutical companies are conducting their own long term outcome trials of some of the newer antihypertensive drugs. Clinical trials are also currently under way in patients with diabetes, heart failure and renal impairment which include both hypertensive and normotensive patients.
community of two extremely able scientists whose papers that we have been happy to accept. Research is an integral part of medical care and should not be contribution to medical research had already been spectacular. 29, 30 seen as something abstruse and so complex that it can only happen in centres which consider themSimilarly, the deaths of Herbert Langford, Tony Amery and Geoffrey Rose has deprived us of great selves to be excellent. It should not be restricted to the ivory towers of academic institutions. Any clinmen whose contributions have been enormous and will continue to be of overwhelming importance. [31] [32] [33] ician working in the field of health care and any suitably trained nurse can formulate a hypothesis which It causes us some sadness that Geoffrey Rose's paper on 'Salt sensitivity in a community in Brazil' could can be tested in a clinical environment, as long as there is careful documentation and a few basic prinnot finally be published in the Journal until after his death. 34 ciples are adhered to after taking appropriate advice.
No one in the future should feel inhibited from We have attempted to keep our Editorial Board young and enthusiastic with regular additions and sending us simple clinical papers even though we as editors may give them a hard time occasionally. sadly some subtractions. When contemplating our successes, we have to pay tribute to the immense importance of our board and also of our referees. many papers (around 50%) and we suspect that we 283-407. have turned away many deserving authors. We hope greeted with enthusiasm, and we are pleased to be 6 Beevers DG. Hypertension in blacks -time for action.
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